Skip to main content
. 2018 May;10(5):2948–2959. doi: 10.21037/jtd.2018.05.55

Figure 4.

Figure 4

The relationship between PFS and gene mutation profile. (A) PFS according to the presence of additional coexisting mutations (ACMs) in IHC+ group (P=0.738), median survival (ACM >7, 260 days vs. ACM ≤7, 202 days); (B) PFS according to the presence of ACMs in IHC+/NGS− group (P=0.801), median survival (ACM >7, 274 days vs. ACM ≤7, 163 days); (C) PFS according to the presence of ACMs in IHC+/NGS+ group (P=0.550), median survival (ACM >7, 244 days vs. ACM ≤7, 370 days); (D) PFS according to mutant TP53 (P=0.712), median survival (mutant TP53, 356 days vs. mild type TP53, 337 days); (E) PFS according to mutant FAT3 (P=0.631), median survival (mutant FAT3 337 days vs. mild type FAT3 356 days). PFS, progression-free survival; IHC, immunohistochemistry; NGS, next generation sequencing.